These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27186714)

  • 1. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH.
    Fischer K; Collins PW; Ozelo MC; Srivastava A; Young G; Blanchette VS
    J Thromb Haemost; 2016 May; 14(5):1105-9. PubMed ID: 27186714
    [No Abstract]   [Full Text] [Related]  

  • 2. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study.
    Hilliard P; Zourikian N; Blanchette V; Chan A; Elliott B; Israels SJ; Nilson J; Poon MC; Laferriere N; Van Neste C; Jarock C; Wu J; McLimont M; Feldman B
    J Thromb Haemost; 2013 Mar; 11(3):460-6. PubMed ID: 23301594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To bleed or not to bleed - is that a question?
    Aledort LM
    J Thromb Haemost; 2010 Jan; 8(1):81-2. PubMed ID: 19874456
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
    Manco-Johnson MJ; Lundin B; Funk S; Peterfy C; Raunig D; Werk M; Kempton CL; Reding MT; Goranov S; Gercheva L; Rusen L; Uscatescu V; Pierdominici M; Engelen S; Pocoski J; Walker D; Hong W
    J Thromb Haemost; 2017 Nov; 15(11):2115-2124. PubMed ID: 28836341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacs.
    Tagliaferri A; Rivolta GF; Rossetti G; Pattacini C; Gandini G; Franchini M
    Thromb Haemost; 2006 Oct; 96(4):542-3. PubMed ID: 17003937
    [No Abstract]   [Full Text] [Related]  

  • 7. The parachute must be properly folded ..
    Donfield SM; Shapiro AD; Gomperts ED; Lynn HS; Usner DW
    J Thromb Haemost; 2007 Mar; 5(3):646-7. PubMed ID: 17092299
    [No Abstract]   [Full Text] [Related]  

  • 8. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.
    Collins PW; Björkman S; Fischer K; Blanchette V; Oh M; Schroth P; Fritsch S; Casey K; Spotts G; Ewenstein BM
    J Thromb Haemost; 2010 Feb; 8(2):269-75. PubMed ID: 19943875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.
    Collins P; Faradji A; Morfini M; Enriquez MM; Schwartz L
    J Thromb Haemost; 2010 Jan; 8(1):83-9. PubMed ID: 19817995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis.
    den Uijl IE; Fischer K
    Thromb Haemost; 2008 May; 99(5):965; author reply 966-8. PubMed ID: 18449430
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
    Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
    Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis in people with haemophilia.
    Coppola A; Franchini M; Tagliaferri A
    Thromb Haemost; 2009 Apr; 101(4):674-81. PubMed ID: 19350110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
    Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
    Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
    Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
    Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
    Mancuso ME; Reding MT; Negrier C; Kerlin BA; Rangarajan S; Simpson ML
    Thromb Haemost; 2021 Aug; 121(8):1079-1086. PubMed ID: 33296943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study.
    Stemberger M; Kallenbach F; Schmit E; McEneny-King A; Germini F; Yeung CHT; Edginton AN; von Mackensen S; Kurnik K; Iorio A
    Thromb Haemost; 2019 Mar; 119(3):368-376. PubMed ID: 30685872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for the benefits of prophylaxis in the management of hemophilia A.
    Hoots WK; Nugent DJ
    Thromb Haemost; 2006 Oct; 96(4):433-40. PubMed ID: 17003919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of arthropathy in haemophilia: prophylaxis.
    Santagostino E; Mancuso ME
    Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.